ComprehensiveMetabolicEmpowerment: UnveilingTirzepatide'sMultifacetedFunctions
WhatisTirzepatide?
TirzepatideisanovelmedicationthatisFDAapprovedforthetreatmentoftype2 diabetesmellitusGivenitspotentweightlossproperties,buytirzepatidebeused off-labelforobesitytreatment
ItworksasadualGLP-1agonistandGIPagonisttomaximizesimilarbenefitsthat areseenwithGLP-1medicationssuchassemaglutide.Itiscurrentlyimplementedas asecond-linediabetesmedication,similartoGLP-1medications,andgivenasa once-a-weeksubcutaneousinjectable.TheFDAapprovedpeptideTirzepatideinMay 2022.
HowDoesTirzepatideWork?
Tirzepatideisasyntheticpeptide;andadualgastricinhibitorypolypeptide(GIP)and glucagon-likepeptide1(GLP-1)receptoragonist.Itiscomposedof39aminoacids andisananalogofthegastricinhibitorypolypeptide.Functionally,itstimulates insulinreleasefromthepancreasandleadstoareductionofhyperglycemia.In addition,Tirzepatidealsoincreasesthelevelsofadiponectin.Itsdualagonismability leadstoamoresignificantreductionofhyperglycemiathanGLP-1agonistagents aloneandlowerstheuser'sappetite.
TirzepatideBenefits
Tirzepatideisaglucose-dependentinsulinotropicpolypeptide(GIP)receptorand glucagon-likepeptide-1(GLP-1)receptoragonist,whichisFDA-approvedfortreating type2diabetesmellitus.Itisimportanttonotethattirzepatideisnotapprovedfor treatingtype-1diabetesmellitusandhasnotbeenstudiedinpatientswith pancreatitis.TirzepatideisaGIPreceptorandGLP-1receptoragonist,leadingto significantlyimprovedglycemiccontrolintype2diabeticsandsignificantweight reduction.
TirzepatideResults
Patientswithobesityandtype2diabetes(T2D)orwithoverweightandT2Dlostan
estimated344pounds(157%)ofbodyweightwith10mgand15mgoftirzepatide (Mounjaro;EliLillyandCompany),accordingtofindingsfromtheSURMOUNT-2 globalphase3trialSpecifically,tirzepatideat10mgreducedbodyweightby5%or morein792%ofpatientsandreducedaveragebodyweightby128%,whilethe15 mgdosereducedweightin827%ofpatientsanddecreasedaveragebodyweight by14.7%.
TirzepatideusedforWeightLoss
Tirzepatide,isaonce-weeklyinjectiontodecreasebloodsugar.Since2022ithas shownremarkableweight-losseffects,andisonfast-trackdesignationforitsreview forthetreatmentofobesity.Onaverage,patientssawanastoundingweight-lossof over20%oftheirinitialbodyweight.
TirzepatideandBPC157helpswithweightlossbydecreasingfoodintakeand slowingdownhowfastfoodtravelsthroughyourdigestivetractThismayhelpyou feelfullerlongerandreducehowmuchfoodyoueatStudiesshowthisactionmay occurinthebrain
Howitworks:
●Reducehowmuchfoodiseaten.
●Stopstheliverfrommakingandreleasingtoomuchsugar.
king@aasraw.com
●Slowsdownhowquicklyfoodleavesthestomach
●Thebodyreleasesinsulinwhenbloodsugarishigh
●Thebodyremovesexcesssugarfromtheblood
WhatisthedifferencebetweenTirzepatideandSemaglutide?
TirzepatideactsonBOTHGIPandGLP-1receptors,whileSemaglutideactsonlyon GLP-1receptors.Bothdrugsareeffectiveweight-losstreatments.Tirzepatideisa dual-actingGIP(glucose-dependentinsulinotropicpolypeptide)andGLP-1 (glucagon-likepeptide-1)receptoragonist.Bothareintheclassofdrugsknownas incretinmimeticsbuthavesomedifferences.
Lifestylemodificationsandcalorierestrictionwillleadtooverallbetterresults. Benefitsofweightlossisimprovedcomorbiditiesofobesitysuchasdiabetes,high bloodpressure,abnormalbloodlipidsandheartdiseasewhichcanbeseenwithas littleasa5%weightloss
TirzepatideSideEffects
ThemostcommonsideeffectsofTirzepatideincludenausea,diarrhea,decreased appetite,vomiting,constipation,indigestion,andstomach(abdominal)pain.These arenotallthepossiblesideeffectsofTirzepatide.Talktoyourhealthcareprovider
king@aasraw.com
aboutanysideeffectsyoumightexperience
References
[1]Lilly:Phase3TirzepatideResultsShowSuperiorA1CAndBodyWeight ReductionsInType2Diabetes"BusinessInsiderRTTNews19October2021 Archivedfromtheoriginalon28October2021.Retrieved28October2021.
[2]TirzepatidesignificantlyreducedA1Candbodyweightinpeoplewithtype2 diabetesintwophase3trialsfromLilly'sSURPASSprogram"(Pressrelease).Eli LillyandCompany.17February2021.Archivedfromtheoriginalon28October2021. Retrieved28October2021–viaPRNewswire.
[3]Kellaher,Colin(28April2022)."EliLilly'sTirzepatideMeetsMainEndpointsin Phase3ObesityStudy".MarketWatch.DowJonesNewswires.Archivedfromthe originalon29April2022.Retrieved29April2022.
[4]WillardFS,DourosJD,GabeMB,ShowalterAD,WainscottDB,SuterTM,etal. (September2020)"TirzepatideisanimbalancedandbiaseddualGIPandGLP-1 receptoragonist"JCIInsight5(17)doi:101172/jciinsight140532PMC7526454 PMID32730231
king@aasraw.com
[5]FrederickMO,BoyseRA,BradenTM,CalvinJR,CampbellBM,ChangiSM,etal (2021)"Kilogram-ScaleGMPManufactureofTirzepatideUsingaHybrid SPPS/LPPSApproachwithContinuousManufacturing"OrganicProcessResearch &Development25(7):1628–1636
[6]FríasJP,DaviesMJ,RosenstockJ,PérezManghiFC,FernándezLandóL, BergmanBK,etal.(August2021)."TirzepatideversusSemaglutideOnceWeeklyin PatientswithType2Diabetes".TheNewEnglandJournalofMedicine.385 (6):503–515.doi:10.1056/NEJMoa2107519.
king@aasraw.com